Revolutionizing Cancer Care with ctDNA Testing
Blood test to aid cancer treatment and recurrence monitoring now available from a German lab for potentially faster results.
MVZ HPH Institute for Pathology and Hematopathology GmbH has proudly announced a groundbreaking advancement: the launch of HPH MRD, a revolutionary tumor-informed circulating-tumor DNA (ctDNA) blood test optimized for detecting minimal residual disease (MRD) in patients diagnosed with solid tumor cancers. This state-of-the-art blood test leverages the innovative Haystack MRD technology and promises to deliver timely, accurate results that can greatly support patient care.
The HPH MRD test is specifically designed to identify ultralow levels of ctDNA with remarkable sensitivity and specificity, which are crucial for detecting residual or recurrent forms of cancer. Clinicians will now have access to next-generation MRD testing performed directly in Hamburg, Germany, enhancing accessibility and providing a streamlined testing process for patients, thus supporting the quick decision-making needed in cancer care.
"At HPH, our mission is to provide patients and clinicians with the highest quality diagnostic tools to guide personalized cancer care," shares Prof. Markus Tiemann, CEO of MVZ HPH Institute. By utilizing Haystack's cutting-edge MRD technology, the institute can now offer local access to testing that was once only feasible through international sources, leading to improved turnaround times and patient outcomes.
ctDNA MRD testing is reshaping the landscape of cancer care by defining molecular evidence of disease that traditional imaging techniques may overlook. Many cancer treatment plans commence with surgery, often followed by chemotherapy or additional therapies. However, it is crucial to recognize that minute amounts of disease can linger, increasing the risk of recurrence. ctDNA MRD testing plays a pivotal role in identifying cancer-derived DNA fragments in the bloodstream, allowing for not only timely but also precise detection of remaining or recurring cancer.
Dan Edelstein, Vice President & General Manager of Haystack Oncology, notes the importance of accessibility to advanced MRD technologies in Europe. Previously, obtaining such sensitive testing often required international sample shipping, presenting hurdles to timely care. The new licensing agreement with HPH signifies a major leap forward in making next-generation MRD testing a standard part of cancer care beyond the confines of the United States.
Understanding the Technology Behind HPH MRD
The pioneering technology behind the HPH MRD testing process is built on the advanced principles of whole-genome sequencing. By analyzing a patient's tumor tissue, HPH can create personalized patient panels that offer unparalleled insights into ctDNA levels, surpassing conventional testing methods. This unique approach allows for greater accuracy and specificity, crucial for developing effective treatment plans tailored to individual patient needs.
HPH's commitment to compliance with stringent data protection and regulatory standards ensures that all testing and results are securely handled within Germany. This facilitates not only patients' privacy but also aligns with the ethical guidelines mandated in healthcare.
About MVZ HPH Institute for Pathology and Hematopathology
The MVZ HPH Institute for Pathology and Hematopathology, established in 2004, specializes in diagnosing a variety of solid tumors and hematological diseases. With a strong focus on advanced diagnostic methodologies, HPH utilizes an extensive array of techniques including histology, immunohistochemistry, and next-generation sequencing (NGS). The institute is dedicated to helping hematologists and oncologists with precise, actionable diagnoses, thereby facilitating informed treatment decisions for patients.
Commitment to Service and Support
HPH's ethos is rooted in a strong service philosophy. The organization strives to provide ongoing support and expertise to healthcare professionals and patients alike. Each member of the team is dedicated to fostering partnerships that enhance the quality of patient care.
About Haystack Oncology
Haystack Oncology brings together over two decades of leadership in cancer genomics, focusing on the advancement of liquid biopsy technologies. As a wholly-owned subsidiary of Quest Diagnostics, it has pioneered MRD testing with Haystack MRD, designed to detect exceptionally low levels of ctDNA, thereby uncovering residual or recurrent cases of cancer effectively.
This design and development of Haystack MRD in CLIA-certified laboratories ensure its validation and reliability as a laboratory-developed test, contributing to the care continuum on a global scale. The efforts of Haystack Oncology extend beyond testing; they collaborate with biopharmaceutical companies to enhance clinical development programs, supporting the introduction of vital therapeutics into the marketplace.
About Quest Diagnostics
Quest Diagnostics plays a crucial role across the healthcare spectrum, aiming to foster a healthier world, one life at a time. Through comprehensive diagnostic insights derived from laboratory results, they empower individuals and healthcare providers to make informed health decisions. This broad access to clinical laboratory data supports discovery and innovation in the field of healthcare, leading to improved health outcomes for millions.
Frequently Asked Questions
What is the HPH MRD test?
The HPH MRD test is an advanced ctDNA blood test aimed at detecting minimal residual disease in solid tumor cancer patients, utilizing Haystack MRD technology.
Where is the HPH MRD test conducted?
Testing takes place at the MVZ HPH Institute's laboratories located in Hamburg, Germany.
How does ctDNA testing improve cancer care?
ctDNA testing allows for earlier and more accurate detection of residual or recurrent cancer, improving treatment decisions.
What are the benefits of local access to MRD testing?
Local access simplifies the testing process for patients, results in faster turnaround times, and enhances patient comfort and confidence in their care.
Who developed the Haystack MRD technology?
Haystack MRD technology was developed by Haystack Oncology, a subsidiary of Quest Diagnostics, and is based on advanced liquid biopsy techniques.
